Research library

The peptide literature, summarized honestly

Seven peptides. For each: what it is, what the animal studies report, and what nobody knows yet. Every summary names the species and the model, because a finding without its organism is an advertisement, not a result.

Standing note. Everything on this page describes research conducted in laboratory animals — chiefly rats and mice — and in cultured cells. Results in animal models are hypothesis-generating. They are not evidence that any compound has any effect in a human being, and this page contains no information about human use.

All areas Tissue Repair Immunomodulation Dermal Metabolic Host Defense

BPC-157 · Gastric pentadecapeptide · Tissue Repair

BPC-157: three decades of rat studies, and the gap that remains

The most-cited peptide in this library is also the most single-sourced.

What it is

BPC-157 is a synthetic chain of fifteen amino acids — a pentadecapeptide — whose sequence corresponds to a fragment of a larger protein described in human gastric juice, which its originators called "Body Protection Compound." Unlike many peptides, it is reported to be unusually stable in stomach acid, which is part of why so much of the work around it involves the digestive tract.

What the animal literature reports

The published record is dominated by one research network centered in Zagreb, Croatia, which has produced studies on this peptide steadily since the early 1990s. In Wistar and Sprague-Dawley rats, that body of work has reported accelerated healing across a striking range of injury models: Achilles tendon transection, medial collateral ligament rupture, muscle crush injury, chemically induced gastric lesions, experimental colitis, and surgical models such as intestinal anastomosis and fistula. A frequently discussed 2016-era line of work examined tendon fibroblast outgrowth in rat Achilles tendon models. Proposed mechanisms in the rodent literature involve modulation of the nitric-oxide system and of angiogenesis-related signaling, though no single mechanism is settled.

What we don't know

Almost everything that matters for translation. The breadth of positive findings is itself a warning sign to methodologists: compounds reported to improve outcomes in nearly every model they touch are historically rare, and the pattern is more often produced by publication practices than by pharmacology. Independent replication outside the originating network remains sparse. Group sizes are small, blinding of outcome assessment is inconsistently reported, and endpoints vary from study to study. Most importantly, no rigorous, completed human trial of BPC-157 has been published. Whatever the rat data suggest, the honest summary of the human evidence is that there is essentially none.

Model organisms: Wistar and Sprague-Dawley rats; occasional mouse and cell-culture work
Study scale: Small animal cohorts, typically single-laboratory
Human trial status: No rigorous completed trials published
Replication status: Largely confined to one research network; independent replication sparse

Thymosin beta-4 / TB-500 fragment · Actin-binding peptide · Tissue Repair

Thymosin beta-4: the cell's actin manager, cast as a repair molecule

A genuinely important cell-biology protein with a far less settled injury-model record.

What it is

Thymosin beta-4 is a small, 43-amino-acid peptide found in nearly all mammalian cells, where its day job is unglamorous and essential: it binds and sequesters monomeric actin, helping regulate the cytoskeleton that gives cells their shape and mobility. The name "TB-500" generally refers to a short synthetic fragment of the molecule centered on its actin-binding region. The fragment's published literature is considerably thinner than the full-length peptide's, and the two should not be treated as interchangeable.

What the animal literature reports

In murine dermal wound models, full-length thymosin beta-4 has been reported to accelerate wound closure and cell migration. Related work described faster re-epithelialization in rodent and rabbit corneal injury models. The most attention-getting line of research came from cardiac studies: work out of a London laboratory in the 2000s reported that thymosin beta-4 could activate dormant epicardial progenitor cells in adult mouse hearts after experimental myocardial infarction. That finding generated real excitement — and subsequent attempts by other groups to reproduce aspects of it produced mixed results, a disagreement that has never been fully resolved in the literature.

What we don't know

Whether the cardiac regeneration story survives contact with independent replication is the central open question, and it is a cautionary tale worth reading in full. Beyond that: small early-phase human studies in wound and ophthalmic settings have been described in the literature, but large, well-controlled efficacy trials are absent. For the TB-500 fragment specifically, the peer-reviewed record is sparse enough that most claims made about it are extrapolations from full-length thymosin beta-4 work — an extrapolation the published data do not license. The honest position is narrower and more interesting: this is a fundamental cytoskeletal protein whose injury-model literature contains one dramatic, still-disputed finding, and a reader should hold the two apart.

Model organisms: Mice (dermal, cardiac); rodent and rabbit corneal models; cell culture
Study scale: Small-to-moderate animal studies; fragment data especially thin
Human trial status: Small early-phase studies described; no large completed efficacy trials
Replication status: Key cardiac findings contested; independent replication mixed

A researcher's microscope on a laboratory bench in low light — Most of what is known about these peptides was learned at benches like this one — in animals, not people.

GHK-Cu · Copper-binding tripeptide · Dermal

GHK-Cu: a fifty-year-old tripeptide with a mostly in-vitro résumé

Discovered in human plasma in the 1970s; still waiting for a definitive study.

What it is

GHK is one of the smallest peptides in this library: three amino acids — glycine, histidine, lysine — with an unusually strong affinity for copper ions, which is why it is usually written GHK-Cu. It was first isolated from human plasma in the early 1970s, and one of the more reliable observations about it is simply that circulating levels decline substantially with age. What that decline means functionally is far less settled.

What the animal literature reports

In rodent dermal wound models, GHK-Cu has been reported to increase collagen deposition and support wound contraction. The larger share of the literature, however, comes from cell culture: in cultured human fibroblasts, the peptide has been described as shifting the expression of genes involved in extracellular-matrix remodeling, including collagen synthesis and the balance between matrix metalloproteinases and their inhibitors. Broad gene-expression profiling studies have reported that GHK modulates a surprisingly large number of genes in vitro — a result that reads as either remarkable biology or an artifact of the assay conditions, depending on the reader's priors.

What we don't know

The literature is old, fragmented, and heavily in vitro. Much of the modern published work is adjacent to the cosmetics industry, where study designs are small, endpoints are soft, and independent replication is rarely attempted. There are no rigorous clinical trials with meaningful disease endpoints. A dish of fibroblasts making more collagen mRNA is several long inferential leaps away from any statement about tissue in a living organism — and the animal work bridging that gap remains limited to small, dated studies that no independent group has systematically reproduced. Fifty years after its discovery, the definitive experiment — a well-powered, blinded, independently replicated animal study with pre-specified endpoints — has simply never been run, and until it is, GHK-Cu remains a molecule with an intriguing in-vitro profile and an unproven everything else.

Model organisms: Rodent dermal models; predominantly cultured human fibroblasts
Study scale: Small, older animal studies; extensive but heterogeneous in-vitro work
Human trial status: No rigorous trials with disease endpoints; small cosmetic-adjacent studies only
Replication status: Rarely attempted independently; core findings unconfirmed at scale

KPV · α-MSH C-terminal tripeptide · Immunomodulation

KPV: three amino acids and one persistent question about mechanism

A hormone fragment that keeps the anti-inflammatory signal — maybe without the receptor.

What it is

KPV is the three-amino-acid tail — lysine, proline, valine — of alpha-melanocyte-stimulating hormone, a signaling molecule better known for its role in pigmentation. The fragment appears to retain much of the parent hormone's anti-inflammatory activity while lacking its pigmentary effects, which has made it a tidy tool molecule for inflammation researchers.

What the animal literature reports

The best-developed line of work is in murine colitis. In mouse models of chemically induced intestinal inflammation — the DSS and TNBS models are the standard ones — KPV has been reported to reduce inflammation scores and histological tissue damage. A widely discussed series of studies described the peptide entering intestinal epithelial and immune cells through PepT1, a transporter that moves small peptides across the gut lining, and dampening inflammatory signaling once inside, including attenuation of NF-κB pathway activity in cell culture. Follow-on murine experiments from other groups have reported broadly consistent reductions in colitis severity measures.

What we don't know

The mechanism remains genuinely unsettled — which receptor, if any, mediates KPV's effects is a live dispute, since the fragment binds the classical melanocortin receptor poorly or not at all in several assays. The colitis findings, while reported by more than one group, still rest on small animal cohorts with the usual limitations: variable blinding, heterogeneous endpoints, and a chemical injury model whose relevance to naturally occurring intestinal disease is itself debated. There are no published human trials of KPV. It is best understood as a well-behaved laboratory probe of inflammation biology, not a compound with any established significance beyond the bench. That a molecule can be genuinely useful to researchers and simultaneously meaningless to everyone else is a distinction this publication exists to keep sharp, and KPV illustrates it as cleanly as anything in this library.

Model organisms: Mice (DSS and TNBS colitis models); intestinal cell culture
Study scale: Small murine cohorts across a handful of laboratories
Human trial status: None published
Replication status: Core colitis findings reported by multiple groups; mechanism unresolved

LL-37 · Cathelicidin host-defense peptide · Host Defense

LL-37: the body's own antibiotic is more complicated than it sounds

One peptide, two reputations: microbial killer and inflammatory culprit.

What it is

LL-37 is the only cathelicidin-family host-defense peptide humans make: a 37-amino-acid chain, beginning with two leucines, that is cleaved from a precursor protein called hCAP18. It folds into an amphipathic helix — one face oily, one face charged — which lets it insert into and disrupt microbial membranes. It is a genuine component of innate immunity, produced by neutrophils and epithelial surfaces, and it doubles as a signaling molecule that recruits and tunes immune cells.

What the animal literature reports

In mouse infection models — skin, lung, and bloodstream challenges with various bacteria — cathelicidin peptides have been reported to reduce microbial burden, and mice engineered to lack their native cathelicidin show increased susceptibility to certain skin infections. Murine wound models have described roles in re-epithelialization and angiogenesis. But the same literature carries the complication: in rodent models of inflammatory skin disease, elevated LL-37 activity has been implicated in driving pathology rather than preventing it, and the peptide's ability to bind self-DNA and activate immune sensors is a proposed mechanism in autoimmune-adjacent conditions.

What we don't know

How to have the killing without the collateral. In vitro, the window between concentrations that disrupt microbial membranes and those that damage host cells is uncomfortably narrow, and the peptide's behavior changes with salt, serum, and tissue context in ways that make bench results hard to generalize. Small early-stage human studies in chronic wound settings have been described, but nothing approaching definitive. LL-37 is probably the best argument in this library for a general principle: "the body makes it" tells you a molecule is interesting, not that it is simple, safe, or understood. Evolution tuned this peptide for a context — precise timing, local concentrations, an orchestra of co-signals — that no experiment has yet managed to reproduce, and the literature is largely the record of that difficulty.

Model organisms: Mice (infection, wound, and inflammatory-disease models); extensive in-vitro work
Study scale: Many small studies across independent laboratories
Human trial status: Small early-stage studies described; no definitive trials
Replication status: Antimicrobial role well replicated; net effect in disease contexts unresolved

Thymosin alpha-1 · Immunomodulatory peptide · Immunomodulation

Thymosin alpha-1: the outlier with an actual clinical history

Licensed in some countries, debated in the review literature — and still leaning on old evidence.

What it is

Thymosin alpha-1 is a 28-amino-acid acetylated peptide derived from a larger precursor protein, prothymosin alpha. It was originally isolated in the 1970s from thymus tissue — the organ where T cells mature — during a research program that ground up thymic extracts looking for the factors behind the organ's immune role. It is not related to thymosin beta-4 in any meaningful structural way; the shared name is an accident of that extraction history.

What the animal literature reports

In rodent models of infection and immunosuppression, thymosin alpha-1 has been reported to improve markers of T-cell function and survival after microbial challenge. Cell-culture work describes it enhancing dendritic-cell maturation and signaling through toll-like receptors — the immune system's pattern-recognition machinery. Aged-rodent studies have reported partial restoration of immune parameters that decline with age. The rodent record is broader than deep: many models, few of them revisited with modern rigor.

What we don't know

Thymosin alpha-1 is the exception in this library, and honesty requires saying so: unlike the other entries, it has decades of clinical development behind it and is a licensed pharmaceutical in a number of countries for certain indications. But a license is not the same thing as settled evidence. Review literature has repeatedly noted that many supporting trials are older, small, unblinded, or methodologically heterogeneous, and large modern confirmatory trials are scarce. The interesting question it poses is almost historiographic: what should a reader conclude when regulatory acceptance in some jurisdictions coexists with a thin modern evidence base? Our answer is the same as everywhere else on this page — go back to the studies, count the animals or the patients, and check who was blinded.

Model organisms: Rats and mice (infection, immunosuppression, aging models); cell culture
Study scale: Many small rodent studies; older clinical literature of mixed quality
Human trial status: Clinical history exists; large modern confirmatory trials scarce
Replication status: Immunologic mechanisms broadly supported; efficacy evidence debated in reviews

An open notebook with handwritten notes and a fountain pen resting on the page — Reading the methods section is slower than reading the abstract. It is also where the truth lives.

MOTS-c · Mitochondrial-derived peptide · Metabolic

MOTS-c: the peptide hiding inside the mitochondrial genome

A young literature built on a genuinely surprising piece of biology.

What it is

MOTS-c is a sixteen-amino-acid peptide encoded, improbably, within the mitochondrial genome — inside a region long annotated as a structural RNA gene, where conventional wisdom said no additional protein could be hiding. Its identification in the mid-2010s helped establish a small class now called mitochondrial-derived peptides, and that discovery is interesting regardless of what the peptide turns out to do: it means the mitochondrial genome carries more information than the textbooks assumed.

What the animal literature reports

The founding study, published in 2015 by a Los Angeles-area group, reported that MOTS-c improved insulin sensitivity and limited weight gain in mice fed a high-fat diet, with effects mapped to skeletal muscle and to activation of AMPK, a central cellular energy sensor, alongside changes in the folate–methionine cycle. Later mouse work from overlapping groups reported improved performance in treadmill-based exercise-capacity tests and described the peptide moving into the cell nucleus under metabolic stress, where it appears to influence gene expression directly. In parallel, human observational studies have measured circulating MOTS-c levels across age, exercise, and metabolic conditions — measurements, not interventions.

What we don't know

Most things. The interventional literature is roughly a decade old, small, and concentrated in a cluster of collaborating laboratories; independent replication at scale has not yet happened. Mouse metabolic phenotypes are notoriously sensitive to strain, diet composition, housing temperature, and handling — all reasons the field's own methodologists urge caution before treating any single-model result as robust. Interventional human evidence is essentially absent. MOTS-c is best read today as an exciting biological question — what are mitochondrial-derived peptides for? — rather than as a compound about which anything practical is established. If the broader mitochondrial-derived peptide field matures, MOTS-c will likely be remembered as its founding curiosity; whether it becomes anything more than that is a question the next decade of independent replication will have to answer.

Model organisms: Mice (diet-induced metabolic models, exercise tests); cell culture
Study scale: Small cohorts; concentrated among collaborating laboratories
Human trial status: Observational level-measurement only; interventional evidence essentially absent
Replication status: Young literature; independent replication at scale not yet achieved

Before you go

How to read these summaries

Every profile above follows the same skeleton on purpose. "What it is" describes chemistry and origin — the part of the record least likely to be wrong. "What the animal literature reports" is deliberately phrased in the language of reporting, because a published finding is a claim by particular people about particular animals under particular conditions, not a fact about the universe. "What we don't know" is not a disclaimer bolted on for caution's sake; for most of these peptides it is the majority of the story.

When we write that a result "has been reported," we mean we have read the paper and are describing its claim without endorsing it. When we say replication is sparse or a literature is single-sourced, we mean that specifically — it is the single most useful thing to check about any preclinical finding. And when we say human evidence is absent, we mean absent: no registered, completed, rigorous trials that we could locate. The gap between a rodent result and human relevance is not a technicality. It is, historically, where the overwhelming majority of promising preclinical findings have quietly ended. Reading this library well means holding both things at once: the biology is often fascinating, and the evidence is almost always thinner than the enthusiasm surrounding it.